VIR
VIR
NASDAQ · Biotechnology

Vir Biotechnology Inc

$11.30
-0.45 (-3.83%)
Financial Highlights (FY 2026)
Revenue
83.23M
Net Income
-531,763,437
Gross Margin
100.0%
Profit Margin
-638.9%
Rev Growth
-65.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 41.4% 41.4%
Operating Margin -699.2% -629.3% -31.7% -35.1%
Profit Margin -638.9% -606.9% -27.2% -30.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 83.23M 238.62M 113.39M 105.81M
Gross Profit 83.20M 238.53M 46.97M 43.83M
Operating Income -581,938,099 -1,501,560,461 -35,981,507 -37,098,247
Net Income -531,763,437 -1,372,096,024 -30,823,495 -32,439,743
Gross Margin 100.0% 100.0% 41.4% 41.4%
Operating Margin -699.2% -629.3% -31.7% -35.1%
Profit Margin -638.9% -606.9% -27.2% -30.7%
Rev Growth -65.1% -65.1% +24.3% +5.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 432.19M 355.41M
Total Equity — — 459.65M 428.15M
D/E Ratio — — 0.94 0.83
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -581,476,987 -1,583,724,591 -42,153,177 -39,538,454
Free Cash Flow — — -22,930,380 -17,215,226